Dr Critt Farr Aardema, MD | |
3443 W 5600 S, Roy, UT 84067-9103 | |
(801) 773-4840 | |
Not Available |
Full Name | Dr Critt Farr Aardema |
---|---|
Gender | Male |
Speciality | Family Practice |
Experience | 14 Years |
Location | 3443 W 5600 S, Roy, Utah |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1891003265 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 5498540-1205 (Utah) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Mckay Dee Hospital | Ogden, UT | Hospital |
Davis Hospital And Medical Center | Layton, UT | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Tanner Memorial Clinic | 4284547985 | 211 |
News Archive
NovoCure Ltd. presented results yesterday evaluating the Novo-TTF device in vitro and in a pilot clinical trial that showed the device enhanced the efficacy of standard chemotherapy (temozolomide) treatment in newly-diagnosed glioblastoma multiforme (GBM) patients.
Genesis HealthCare, one of the nation's largest providers of post-acute care, today announced that it has filed a shelf registration statement on Form S-3 with the United States Securities and Exchange Commission.
"US health insurers are paying doctors seven days faster, on average, and denying 12 to 18 percent fewer claims than last year, but the claims reimbursement system remains saddled with inefficiency, according to a new ranking of payers set to be released today," The Boston Globe reports.
Buffalo Grove, Illinois-based specialty-oncology drug development company, Meridian Laboratories, Inc (Meridian) held a Type B Pre-Investigational New Drug (pre-IND) meeting with the FDA Center for Drug Evaluation Research, Division of Oncology Products on Wednesday January 23, 2013 to discuss its plan to commence clinical development of ML061, Meridian's lead product, as a treatment for various types of cancer.
› Verified 5 days ago
Entity Name | Ihc Health Services Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1629260880 PECOS PAC ID: 1850209420 Enrollment ID: O20031105000079 |
News Archive
NovoCure Ltd. presented results yesterday evaluating the Novo-TTF device in vitro and in a pilot clinical trial that showed the device enhanced the efficacy of standard chemotherapy (temozolomide) treatment in newly-diagnosed glioblastoma multiforme (GBM) patients.
Genesis HealthCare, one of the nation's largest providers of post-acute care, today announced that it has filed a shelf registration statement on Form S-3 with the United States Securities and Exchange Commission.
"US health insurers are paying doctors seven days faster, on average, and denying 12 to 18 percent fewer claims than last year, but the claims reimbursement system remains saddled with inefficiency, according to a new ranking of payers set to be released today," The Boston Globe reports.
Buffalo Grove, Illinois-based specialty-oncology drug development company, Meridian Laboratories, Inc (Meridian) held a Type B Pre-Investigational New Drug (pre-IND) meeting with the FDA Center for Drug Evaluation Research, Division of Oncology Products on Wednesday January 23, 2013 to discuss its plan to commence clinical development of ML061, Meridian's lead product, as a treatment for various types of cancer.
› Verified 5 days ago
Entity Name | Tanner Memorial Clinic |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1447239355 PECOS PAC ID: 4284547985 Enrollment ID: O20031110000132 |
News Archive
NovoCure Ltd. presented results yesterday evaluating the Novo-TTF device in vitro and in a pilot clinical trial that showed the device enhanced the efficacy of standard chemotherapy (temozolomide) treatment in newly-diagnosed glioblastoma multiforme (GBM) patients.
Genesis HealthCare, one of the nation's largest providers of post-acute care, today announced that it has filed a shelf registration statement on Form S-3 with the United States Securities and Exchange Commission.
"US health insurers are paying doctors seven days faster, on average, and denying 12 to 18 percent fewer claims than last year, but the claims reimbursement system remains saddled with inefficiency, according to a new ranking of payers set to be released today," The Boston Globe reports.
Buffalo Grove, Illinois-based specialty-oncology drug development company, Meridian Laboratories, Inc (Meridian) held a Type B Pre-Investigational New Drug (pre-IND) meeting with the FDA Center for Drug Evaluation Research, Division of Oncology Products on Wednesday January 23, 2013 to discuss its plan to commence clinical development of ML061, Meridian's lead product, as a treatment for various types of cancer.
› Verified 5 days ago
Entity Name | Utah Wound Care And Hyperbaric Center Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1639815483 PECOS PAC ID: 2668849167 Enrollment ID: O20221111001209 |
News Archive
NovoCure Ltd. presented results yesterday evaluating the Novo-TTF device in vitro and in a pilot clinical trial that showed the device enhanced the efficacy of standard chemotherapy (temozolomide) treatment in newly-diagnosed glioblastoma multiforme (GBM) patients.
Genesis HealthCare, one of the nation's largest providers of post-acute care, today announced that it has filed a shelf registration statement on Form S-3 with the United States Securities and Exchange Commission.
"US health insurers are paying doctors seven days faster, on average, and denying 12 to 18 percent fewer claims than last year, but the claims reimbursement system remains saddled with inefficiency, according to a new ranking of payers set to be released today," The Boston Globe reports.
Buffalo Grove, Illinois-based specialty-oncology drug development company, Meridian Laboratories, Inc (Meridian) held a Type B Pre-Investigational New Drug (pre-IND) meeting with the FDA Center for Drug Evaluation Research, Division of Oncology Products on Wednesday January 23, 2013 to discuss its plan to commence clinical development of ML061, Meridian's lead product, as a treatment for various types of cancer.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Critt Farr Aardema, MD Po Box 337, Layton, UT 84041-0337 Ph: (801) 773-4840 | Dr Critt Farr Aardema, MD 3443 W 5600 S, Roy, UT 84067-9103 Ph: (801) 773-4840 |
News Archive
NovoCure Ltd. presented results yesterday evaluating the Novo-TTF device in vitro and in a pilot clinical trial that showed the device enhanced the efficacy of standard chemotherapy (temozolomide) treatment in newly-diagnosed glioblastoma multiforme (GBM) patients.
Genesis HealthCare, one of the nation's largest providers of post-acute care, today announced that it has filed a shelf registration statement on Form S-3 with the United States Securities and Exchange Commission.
"US health insurers are paying doctors seven days faster, on average, and denying 12 to 18 percent fewer claims than last year, but the claims reimbursement system remains saddled with inefficiency, according to a new ranking of payers set to be released today," The Boston Globe reports.
Buffalo Grove, Illinois-based specialty-oncology drug development company, Meridian Laboratories, Inc (Meridian) held a Type B Pre-Investigational New Drug (pre-IND) meeting with the FDA Center for Drug Evaluation Research, Division of Oncology Products on Wednesday January 23, 2013 to discuss its plan to commence clinical development of ML061, Meridian's lead product, as a treatment for various types of cancer.
› Verified 5 days ago
Kurtis Don Ellis, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1915 W 5950 S, Roy, UT 84067 Phone: 801-387-8100 Fax: 801-475-1621 | |
Diane Eh Wilson, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1937 W 5700 S, Roy, UT 84067 Phone: 801-773-9380 | |
Jared Don Hiatt, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1915 W 5950 S, Roy, UT 84067 Phone: 801-387-8100 | |
Dr. Brent E Wallace, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1915 W 5950 S, Roy, UT 84067 Phone: 801-387-8100 | |
Kelly R Amann, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3485 W 5200 S, Roy, UT 84067 Phone: 801-475-3900 Fax: 801-475-3901 | |
Dr. John R Wood, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1915 W 5950 S, Roy, UT 84067 Phone: 801-387-8100 | |
Dr. Isaac Samuel Sparks, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1915 W 5950 S, Family Medicine, Roy, UT 84067 Phone: 801-387-8100 Fax: 801-387-8223 |